



ASX Announcement

CLEANSING NOTICE

Melbourne, Australia, 9 April 2026

Further to its ASX announcement of 27 March 2026, Lumos Diagnostics Holdings Limited (ASX: LDX) (**Lumos** or the **Company**) advises it has issued 88,888,876 fully paid ordinary shares (**Shares**) at an issue price of A\$0.225 per Share.

Lumos issued the Shares without disclosure under section 708A(5) of the *Corporations Act 2001* (Cth) (**Act**) and, in accordance with section 708A(6) of the Act, gives notice under section 708A(5)(e) of the Act that:

1. the Shares were issued without disclosure under Part 6D.2 of the Act; and
2. as at the date of this notice:
 - (a) the Company has complied with the provisions of Chapter 2M of the Act as they apply to the Company;
 - (b) the Company has complied with sections 674 and 674A of the Act; and
 - (c) there is no excluded information within the meaning of sections 708A(7) and 708A(8) of the Act which is required to be disclosed under section 708A(6)(e) of the Act.

- ENDS -

This announcement has been approved by the Lumos Disclosure Committee.

About Lumos Diagnostics,

Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.

For more information visit lumosdiagnostics.com.

Forward-Looking Statements

This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.

Media Contacts:

Tom Trezona – Australia
H^CK Acting Managing Director
tom@hck.digital
+61 411 235 692

Investor Contact:

George Kopsiaftis
IR Specialist, IR Department
ir@lumosdiagnostics.com
+61 409 392 687

Company Registered Office:

Lumos Diagnostics Holdings Ltd
Suite 2, Level 11
385 Bourke Street
Melbourne VIC 3000
info@lumosdiagnostics.com
+61 3 9087 1598